A first-in-class PD1-IL18 immunocytokine (BPT567) targets PD-1+ IL18R+ CD8+ T effector cells enriched in the tumor microenvironment and exhibits potent antitumor efficacy with excellent tolerability

BPT567 - Bright Peak Therap

https://www.abstractsonline.com/pp8/#!/10828/presentation/3553

Jean-Philippe Carralot1; Kea Martin1; Rubén Alvarez Sanchez1; Roy Meoded1; Caoimhe Herr1; Philipp Moosman1; Arnaud Goepfert1; Andrew Chi2; Vijaya J. Pattabiraman1; Bertolt Kreft1

Mar 14, 2023